-+ 0.00%
-+ 0.00%
-+ 0.00%

HUTCHMED ANNOUNCES NDA ACCEPTANCE IN CHINA WITH PRIORITY REVIEW STATUS FOR FANREGRATINIB IN SECOND-LINE INTRAHEPATIC CHOLANGIOCARCINOMA

路透·12/29/2025 08:35:56

登录查看新闻详情